Results 21 to 30 of about 21,470 (167)

CD47 regulates antigen modulation and red blood cell clearance following an incompatible transfusion

Frontiers in Immunology
Red blood cell (RBC) alloantibodies can result in the rapid removal of incompatible RBCs following transfusion. However, antibody-mediated clearance of RBCs is not the inevitable outcome of an incompatible transfusion. Antibody engagement can also result
Ryan P. Jajosky, Ryan P. Jajosky, Mischa L. Covington, Mischa L. Covington, Jun Liu, Jun Liu, Li Chai, Patricia E. Zerra, Patricia E. Zerra, Patricia E. Zerra, Satheesh Chonat, Satheesh Chonat, Sean R. Stowell, Sean R. Stowell, Connie M. Arthur, Connie M. Arthur   +15 more
doaj   +1 more source

Bispecific antibody approach for EGFR-directed blockade of the CD47-SIRPα “don’t eat me” immune checkpoint promotes neutrophil-mediated trogoptosis and enhances antigen cross-presentation

OncoImmunology, 2020
Cancer cells overexpress CD47 to subvert phagocytic elimination and evade immunogenic processing of cancer antigens. Moreover, CD47 overexpression inhibits the antibody-dependent cellular phagocytosis (ADCP) and cytotoxicity (ADCC) activities of ...
Mark A. J. M. Hendriks, Emily M. Ploeg, Iris Koopmans, Isabel Britsch, Xiurong Ke, Douwe F. Samplonius, Wijnand Helfrich   +6 more
doaj   +1 more source

Phase 1 dose escalation and expansion trial of the bispecific CD47 inhibitor and CD40 agonist Fc-fusion protein SL-172154 (SIRPα-Fc-CD40L) in patients with higher-risk myelodysplastic syndrome or acute myeloid leukemia. [PDF]

Cancer
Abstract Background This clinical trial sought to determine whether SL‐172154 could be combined safely and improve the efficacy of azacitidine (AZA) in patients with higher‐risk myelodysplastic syndrome (HR‐MDS) or acute myeloid leukemia (AML). Methods Dose escalation: doses of 1, 3, and 6 mg/kg SL‐172154 was evaluated as monotherapy or in combination ...
Daver NG, Zeidan AM, Stein AS, Zeidner JF, Maher K, Curran E, Bixby D, Chai-Ho W, Stahl M, Yee KWL, Stevens D, Ito S, Reynolds J, Medd P, Searle E, Sochacki A, Savoie ML, Green S, Kato K, Hernandez R, Metenou S, Ma B, Pandite L, Schreiber TH, Sallman DA.   +24 more
europepmc   +2 more sources

SIRPα - CD47 axis regulates dendritic cell-T cell interactions and TCR activation during T cell priming in spleen

PLoS ONE, 2022
The SIRPα-CD47 axis plays an important role in T cell recruitment to sites of immune reaction and inflammation but its role in T cell antigen priming is incompletely understood.
Anu Autio, Huan Wang, Francisco Velázquez, Gail Newton, Charles A. Parkos, Pablo Engel, Daniel Engelbertsen, Andrew H. Lichtman, Francis W. Luscinskas   +8 more
doaj   +2 more sources

Mitigating of the interference of anti-CD47 monoclonal antibody on transfusion compatibility detection

Zhongguo shuxue zazhi, 2023
Objective To evaluate the interference of anti-CD47 monoclonal antibody on transfusion compatibility detection, in order to establish methods for removing interference and evaluate its efficacy. Methods Blood samples from 8 patients in our clinical trial
Yiyang LYU, Wenbing KONG, Xiaogang CHEN, Chixiang LIU, Piao LYU, Hui ZHAO, Xue LIN, Huayou ZHOU   +7 more
doaj   +1 more source

A Novel Affinity Engineered Anti-CD47 Antibody With Improved Therapeutic Index That Preserves Erythrocytes and Normal Immune Cells

Frontiers in Oncology, 2022
Therapeutic blockade of the CD47/SIRPα axis by small molecules or monoclonal antibodies (mAbs) is a proven strategy to enhance macrophages-mediated anti-tumor activity.
Youg R. Thaker, Ianne Rivera, Ianne Rivera, Christophe Pedros, Christophe Pedros, Alok R. Singh, Laura Rivero-Nava, Heyue Zhou, Barbara A. Swanson, Barbara A. Swanson, Lisa Kerwin, Yanliang Zhang, J. Dixon Gray, Gunnar F. Kaufmann, Gunnar F. Kaufmann, Henry Ji, Robert D. Allen, Damien Bresson   +17 more
doaj   +1 more source

Microfluidic Nano‐Assembly of Red‐Blood‐Cell (RBC) Lipids and Components for Engineering Extracellular Vesicles

Advanced Healthcare Materials, EarlyView.
Engineered red blood cell‐derived extracellular vesicles (eRBCEVs) are synthesized via controlled microfluidic assembly from native RBC lipids, enabling tunable encapsulation of proteins, nucleic acids, nanoparticles, and viral vectors. The platform demonstrates reproducible nanoscale architecture, preserved membrane composition, and functional cargo ...
Chiranth K. Nagaraj, Xilal Y. Rima, Kim T. Nguyen, Courtney Culkins, Nana Boateng, Jacob Doon‐Ralls, Alejandro Bresolin, Xin Huang, Hong Li, Vahedi Amid, Ajeet Pal Singh, Dharti Shantaram, Anastasiia Amari, Mangesh D. Hade, Nicholas R. Merriam, Zachary D. Schultz, Scott Q. Harper, Nizar Y. Saad, Setty M. Magaña, Willa A. Hsueh, Rachel E. Kopec, Blaise R. Kimmel, Andre F. Palmer, Eduardo Reátegui   +23 more
wiley   +1 more source

Comprehensive In Vitro Profiling Demonstrates Successful Immune Evasion of Bioengineered Immune‐Shielded Heart Valves

Advanced Healthcare Materials, EarlyView.
Living donor heart valves offer superior durability for pediatric patients but trigger immune rejection. Lentiviral delivery of viral immune‐evasion genes US2 and Serpin b9 into donor valve cells and valve tissue suppresses HLA expression, reduces PBMC clustering and cytotoxic killing, and induces transcriptional immune‐tolerance programs, paving the ...
Abraham van Wijk, Leanne Van den Berg, Isa B. M. Velraeds, Valentina Osorio Zuluaga, Emma T. M. Peereboom, Martijn J. W. E. Rabelink, Arnaud Zaldumbide, Rob C. Hoeben, Marie‐Jose T. H. Goumans, Eric Spierings, Carlijn V. C. Bouten, Marijn C. Peters   +11 more
wiley   +1 more source

Advanced Materials for Biologics Delivery to Brain Tumors

Advanced Materials, EarlyView.
Material innovation is central to unlocking the therapeutic potential of biologics against many central nervous system diseases, including brain cancer. By engineering carriers with controlled transport, targeting, and release properties, advanced materials can overcome the blood–brain barrier and tumor microenvironment, improving the delivery of ...
Yuran Feng, Yuxue Cao, Maria Kavallaris, Taskeen Janjua, Amirali Popat   +4 more
wiley   +1 more source

Cell‐Based Biohybrid Micro/Nanorobots for Biotherapy

Advanced Robotics Research, EarlyView.
This review systematically evaluates cell‐based biohybrid micro/nanorobots (CB‐BMRs), highlighting their cell selection criteria, fabrication strategies, and diverse actuation modes. Furthermore, it surveys the promising therapeutic applications of CB‐BMRs in targeted cancer, thrombosis, and inflammation treatments, while comprehensively discussing ...
Lin Wang, Chenlu Liu, Yu Zhao, Chuanhua Li, Xuyang Chen, Shixiao Ding, Lizhou Dai, Guokun Wang, Tianlong Li, Jiaxin Li, Xuejia Liu, Haocheng Wang   +11 more
wiley   +1 more source